ReviewOral and maxillofacial surgery2025
Role of stereotactic radiotherapy for head neck cancer.
Review in Oral and maxillofacial surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn recent years, stereotactic ablative radiotherapy (SABR) has been created. Using one or a small number of dosage fractions, SABR enables the hypofractionated treatment of extracranial tumours, delivering a high biologically effective dose with little damage. This review article explores role of stereotactic ablative radiotherapy in head neck cancers. MATERIAL
methodsUsing the search parameters SABR, stereotactic radiotherapy, and targeted radiation, the publications were found on PubMed and Scopus. For this review, the closest publications to SABR were consulted from the search results that were returned.
conclusionIn the treatment of patients with recurring and/or previously irradiated head and neck malignancies, SABR is technically possible, well-tolerated, and performs comparably to other salvage therapy options. It also offers the benefit of a quicker course of therapy. Timetable, increased adherence, and secure delivery in the outpatient context. This presents a chance to provide SABR as a therapy option for a limited number of patients. In order to properly administer a highly conformal ablative dosage to targets (or tumours) in the body, SBRT requires sophisticated technologies in radiation planning and imaging guiding. Because of its highly conformal dose distributions and stereotactic spatial precision in administration, SABR is being employed more and more to treat a range of head and neck tumours.
Indexed as
Identifiers
40000480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.